Day: February 7, 2024

IRVINE, CA., Feb. 07, 2024 (GLOBE NEWSWIRE) — Clean Energy Technologies, Inc. (NASDAQ: CETY), a clean energy manufacturing and services company, offering eco-friendly green energy solutions, clean energy fuels, and alternative electric power for small and mid-sized projects in North America, Europe, and Asia announced today that Vermont Renewable Gas, LLC (VRG), an affiliate limited liability company, has received a favorable order from the State of Maine Public Utilities Commission (PUC). The order grants New Renewable Resource Certification status for VRG – Lyndon, a 2.2 MW biogas generator facility under development in Lyndonville, Vermont. In recent months, VRG initiated a request with the Maine PUC for certification as a qualified generator under Maine’s Renewable Portfolio Standard (RPS). In January 2024, the PUC announced...

Tokyo, Feb. 07, 2024 (GLOBE NEWSWIRE) — Lead Real Estate Co., Ltd (Nasdaq: LRE) (“LRE” or the “Company”), a Japanese real estate developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture and Sapporo, today announced the receipt of contracts to construct three luxury family type hotels in Japan. A nine-floor property, ENT TERRACE ASAKUSABASHI in Tokyo, made from reinforced concrete, will have six rooms, a building area of 4,523 square feet, land area of 924 square feet, and began construction in January 2024. The ENT TERRACE GINZA 3rd STREET, also in Tokyo, with seven above-ground floors and one basement featuring a restaurant and shops, will be made from steel and reinforced concrete, have six rooms, a building area of 4,493 square feet and land area of 906 square...

DUBLIN, Ireland, Feb. 07, 2024 (GLOBE NEWSWIRE) — Trinity Biotech Plc. (Nasdaq: TRIB) (the “Company”) today announced that its New York based reference laboratory, Immco Diagnostics, has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjögrens Syndrome Test Panel, to allow for an optimised market access strategy to deliver broader patient access and improved profitability. It is estimated that up to approximately 3 million people in the US have Sjögrens Syndrome, making it one of the most prevalent autoimmune syndromes. Individuals with Sjögrens Syndrome suffer most notably from dry eyes and dry mouths, as well as difficulty swallowing, increased dental cavities, joint pain and swelling, among other ailments. There is an acute shortage of evidence-based standardized screening tools for Sjögren’s Syndrome,...

Following a successful collaboration with the US Air Force in SBIR Award Phase 1, ZenaDrone has gained significant traction in acquiring additional contracts valued at $1.2 million CHICAGO, IL, Feb. 07, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – Epazz, Inc. (OTC Pink: EPAZ), a mission-critical provider of drone technology, blockchain mobile apps, and cloud-based business software solutions, has announced today that its holdings company ZenaDrone, Inc., a company known for its multi-patented drone technology, is excited to announce flight demonstrations of ZenaDrone 1000 with several units of the US Air Force. The flight demonstrations are instrumental for ZenaDrone to obtain memorandums of understanding (MOUs), which are essential to winning up to $1.2 million for the SBIR Phase 2 contract. Following a successful collaboration...

SUGAR LAND, Texas, Feb. 07, 2024 (GLOBE NEWSWIRE) —  CVR Partners, LP (NYSE: UAN), a manufacturer of ammonia and urea ammonium nitrate (UAN) solution fertilizer products, plans to release its fourth quarter and full-year 2023 earnings results on Tuesday, February 20, after the close of trading on the New York Stock Exchange. The Partnership also will host a teleconference call on Wednesday, February 21, at 11 a.m. Eastern to discuss these results. This call, which will contain forward-looking information, will be webcast live and can be accessed on the Investor Relations section of CVR Partners’ website at www.CVRPartners.com. For investors or analysts who want to participate during the call, the dial-in number is (877) 407-8029. The webcast will be archived and available for 14 days at https://edge.media-server.com/mmc/p/ep887atw/....

MISSISSAUGA, Ontario, Feb. 07, 2024 (GLOBE NEWSWIRE) — KP Tissue Inc. (“KPT”) (TSX:KPT), which holds an interest in Kruger Products Inc. will release the financial results for KPT and Kruger Products Inc. for the fourth quarter of 2023 on Thursday, March 7, 2024 before the market opens. KPT will hold its conference call the same day at 8:30 a.m. Eastern Time. Details of the Conference Call Via telephone: 1-888-664-6383 or 416-764-8650Via the internet at: www.kptissueinc.com Presentation material referenced during the conference call will be available at www.kptissueinc.com Conference Call Rebroadcast A rebroadcast of the conference call will be available until midnight, March 14, 2024 by dialing 1-888-390-0541 or 416-764-8677 and entering passcode 631417. The replay of the webcast will remain available on the web site until midnight,...

SUGAR LAND, Texas, Feb. 07, 2024 (GLOBE NEWSWIRE) — CVR Energy, Inc. (NYSE: CVI) plans to release its fourth quarter and full-year 2023 earnings results on Tuesday, February 20, after the close of trading on the New York Stock Exchange. The Company also will host a teleconference call on Wednesday, February 21, at 1 p.m. Eastern to discuss these results. This call, which will contain forward-looking information, will be webcast live and can be accessed on the Investor Relations section of CVR Energy’s website at www.CVREnergy.com. For investors or analysts who want to participate during the call, the dial-in number is (877) 407-8291. The webcast will be archived and available for 14 days at https://edge.media-server.com/mmc/p/db86jutg/. A repeat of the call also can be accessed for 14 days by dialing (877) 660-6853, conference...

DUARTE, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) — iPower Inc. (Nasdaq: IPW) (“iPower” or the “Company”), a tech and data-driven online retailer and supplier of consumer home and garden products, as well as a provider of value-added ecommerce services, will host a conference call on Wednesday, February 14, 2024 at 4:30 p.m. Eastern time to discuss its financial results for the fiscal second quarter ended December 31, 2023. The Company’s results will be reported in a press release prior to the call. iPower management will host the conference call, followed by a question-and-answer period. Date: Wednesday, February 14, 2024Time: 4:30 p.m. Eastern timeDial-in registration link: hereLive webcast registration link: here Please dial into the conference call 5-10 minutes prior to the start time. If you have any difficulty connecting with...

LOS ANGELES, CA, Feb. 07, 2024 (GLOBE NEWSWIRE) — via NewMediaWire – LiveOne (Nasdaq: LVO), an award-winning, creator-first music, entertainment, and technology platform, announced today the appointment of Aaron Sullivan as CFO. Mr. Sullivan previously served as Vice President, Corporate Controller, and as LiveOne’s Interim Chief Financial Officer. Robert Ellin, Chairman and CEO of LiveOne, commented, “Aaron has been with LiveOne since March 2019 and for the past two years, he has done an incredible job serving as the interim CFO. During this period, it became obvious to everyone Aaron brings the right talent and experiences and has been an instrumental leader strengthening our financial and operational management.” About LiveOne, Inc. LiveOne, Inc. is an award-winning, creator-first, music, entertainment, and technology...

Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board. Dr. Boger is an innovative scientist and highly successful business executive who brings extensive drug development and biopharmaceutical company leadership experience to CervoMed as it progresses toward an important inflection point. Topline data from the RewinD-LB Phase 2b clinical...